

Special Issue

Molecular Research of Neuroinflammation and Neurogenesis

Message from the Guest Editor

The nature of neurogenesis and its integration into a functional circuit is more complex than for other cells. We are relatively certain that widespread differences in neurogenesis, such as larger brain sizes in males than females, larger eye sizes in females than males, and a higher neurogenesis in young individuals, have become accepted in this field. As illustrated in the beautiful drawings of Santiago Ramon y Cajal of the brain, we are equally sure that it is only possible in some individuals for the consequences of neurogenesis to lead to illness or mortality. Together, we must test the concept of differences in neurogenesis as a disease neuropathology and illustrate the idea of neurogenesis as evolutionary constrained, genetical organized developmental processes emerge from a wide range of studies, including neurogenetics and neurobiology. In this Special Issue, we welcome papers that focus on molecular biology and treatments of diseases, which aid in understanding the importance of both basic neurogenesis and clinical-related disease treatment studies: Neuroinflammation and neurogenesis; Neurogenesis and brain glial cells and microglia; Neurogenesis and neurodegeneration.

Guest Editor

Dr. Hui-Yun Chang

Institute of Systems Neuroscience, National Tsing Hua University,
Hsinchu City 30013, Taiwan

Deadline for manuscript submissions

closed (31 March 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/121301

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).